Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Key Event: Completion of Consolidation (Exhibit 99.1)
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate structural changes rather than operational financial performance for the period.
Material Changes
- Corporate Structure: The company reports the "Completion of Consolidation" as the primary material event for this period.
- Registration Statements: This report is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the notification of the consolidation completion.
Key Facts for Investor Verification
- Verify the specific terms and impact of the "Completion of Consolidation" referenced in Exhibit 99.1.
- Confirm the status of the referenced Form S-8 and Form F-3 registration statements to understand potential equity issuance plans.
- Review the company's most recent Form 20-F for detailed financial statements, as this Form 6-K contains no financial data.